SCHEMBL1262282

SCHEMBL1262282

COc1ncc(-c2cc(Cl)nc(-c3cccc(NC(=O)C4CCN(C(=O)OC(C)(C)C)CC4)c3)n2)c(OC)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MGLL Q99685 4/20 0.42
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
STS P08842 2/20 0.41
GPR119 Q8TDV5 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SCN9A Q15858 1/20 0.39
MALT1 Q9UDY8 1/20 0.39
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27682780 0.87 PTPN2 (0.46) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL1262554 0.85 PTPN1 (0.60) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL4604178 0.82 PTPN2 (0.50) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL1262989 0.77 PTPN1 (0.50) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL1264089 0.75 ITGA2B (0.44) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL23086091 0.72 STS (0.67) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL8698926 0.70 PTPN2 (0.55) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL4605845 0.69 PTPN1 (0.50) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL13676224 0.69 PTPN2 (0.68) PTPN2PTPN1PTPN6NPC1RAB9A
SCHEMBL18464304 0.68 PTPN2 (0.67) PTPN2PTPN1PTPN6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893063-B2 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer ASTRAZENECA AB (SE) 2011-02-22 US disclosed
US-20090143384-A1 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer ASTRAZENECA UK LIMITED (GB) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143384-A1 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer PIK3CA, PIK3CB, TYMP PTPN2 1729/4885PTPN1 1727/4885PTPN6 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.